Physician profile
Robert E Noh
NPI 1962417303
$5,300.53
in general payments reported to CMS, 2019-2025
34 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $445 · 2021: $692 · 2022: $852 · 2023: $686 · 2024: $721 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.30 |
| Education | $349.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,434.48 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Antares Pharma, INC. | $517.90 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $503.39 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $339.48 | 2019-2025 | |
| Allergan, INC. | $269.02 | 2019-2022 | |
| Abbvie INC. | $243.89 | 2020-2025 | |
| Janssen Biotech, INC. | $230.15 | 2020-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $225.03 | 2019-2025 | |
| Myovant Sciences INC. | $175.92 | 2021-2022 | |
| Tolmar, INC. | $174.77 | 2023-2025 | Eligard |
| Endo Pharmaceuticals INC. | $143.12 | 2020-2024 | Xiaflex, Aveed |
| 180 Medical, INC. | $132.58 | 2021-2025 | |
| Medical Device Business Services, INC. | $117.19 | 2019 | |
| Endo USA, INC. | $69.82 | 2025 | Xiaflex, Aveed |
| Neotract INC. | $67.07 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $64.86 | 2022 | |
| Halozyme INC | $64.18 | 2023 | |
| Clarus Therapeutics INC. | $62.38 | 2021 | |
| Urovant Sciences INC | $60.03 | 2021-2022 | |
| Boston Scientific Corporation | $54.49 | 2020-2024 | |
| Axonics, INC. | $47.98 | 2021 | |
| Procept Biorobotics Corporation | $44.25 | 2025 | |
| Civco Medical Instruments | $40.74 | 2025 | |
| Progenics Pharmaceuticals, INC. | $30.08 | 2025 | |
| Janssen Scientific Affairs, LLC | $29.12 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $27.99 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $19.84 | 2023 | |
| Azurity Pharmaceuticals, INC. | $18.58 | 2025 | Azmiro |
| Palette Life Sciences, INC. | $18.07 | 2022 | |
| Metuchen Pharmaceuticals | $15.62 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.00 | 2024 | Exparel |
| Olympus America INC. | $14.93 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.71 | 2024 | Adstiladrin |
| Baxter Healthcare | $13.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Noh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.